RiDYMO® Designs Cyclic Peptide for “Undruggable” β-Catenin Target Within Two Months

BEIJING, Jan. 8, 2025 /PRNewswire/ — In a recent achievement, DP Technology’s hit discovery platform RiDYMO® has successfully designed a cyclic peptide targeting β-catenin, a historically “undruggable” protein, in just two months. This innovative AI-driven approach combines advanced…